Is there a role for tissue plasminogen activator (tPA) as a novel treatment for refractory COVID-19 associated acute respiratory distress syndrome (ARDS)?
The global pandemic of COVID-19 has begun to oversaturate the world's medical capacity to accommodate a large surge of patients with acute respiratory distress syndrome (ARDS). Acute respiratory distress syndrome has no effective treatment besides supportive care, with the use of ventilatory st...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
Ovid Technologies (Wolters Kluwer Health)
2020
|
| Online Access: | https://hdl.handle.net/1721.1/124892 |